Skip to content

Clinical trials

Observational Giant Cell Arteritis trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Giant Cell Arteritis Phase: Observational Clear all

79 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20051
20061
20091
20104
20113
20123
20131
20146
20154
20163
20172
20182
20194
202010
20213
20223
20236
20247
20257
20268

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed30
Recruiting25
Unknown status9
Not yet recruiting7
Terminated4
Active, not recruiting3
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Centre Hospitalier Universitaire Dijon5
University of Pennsylvania5
University of South Florida5
University Hospital, Brest4
University of Aarhus4
University of Bonn4
University of Oxford4
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal3
Fondation Ophtalmologique Adolphe de Rothschild3
Groupe français d'étude des Maladies Inflammatoires de loeil3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Giant Cell Arteritis79
Polymyalgia Rheumatica16
Takayasu Arteritis15
Vasculitis11
Granulomatosis with Polyangiitis10
Polyarteritis Nodosa10
Arthritis, Rheumatoid9
Behcet Syndrome9
Microscopic Polyangiitis9
Churg-Strauss Syndrome8

Trials

Showing 51 to 75 of 79. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.